EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: whitephosphorus who wrote (832)	5/7/1998 9:37:00 AM
From: Brian Malloy	Read Replies (1) of 2135

Gee how nice of Onconase, what a great piece of self serving publicity trying to ride on the coattails of EntreMed. I really enjoyed "Tamoxifen alone has absolutely no effect on pancreatic adenocarcinoma." I would trust that this company knows that Tamoxifen is not used for pancreatic adenocarcinoma. As for "Our responsibility to humanity is obvious. We ought to make Onconase available to everyone stricken with cancer". I hope they are not implying that Onconase is indicated for every type of cancer. The other little part that is quite a hoot: "In fact, the universal and ubiquitous nature of RNA in living systems offers an array of opportunities for Onconase as a therapeutic agent. By virtue of its ribonuclease (RNase) character, Onconase has the potential to destroy living systems that are offensive to human life." No duh, the oceans are full of salt water and we should not forget about the ubiquitous nature of DNA in living systems either. Where did you get this article, Who wrote this stuff? I hope it wasn't you Will. Regards, Brian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next